Site Feasibility & Selection
Validated Site Strategy
Deep partnerships with Korea's leading clinical trial centers.
Site strategy built on real evidence — patient population data, indication-specific intelligence, and direct hospital partnerships.
ACRO works with sponsors to design feasibility strategies grounded in what's actually true, not what's hoped to be.
Related reading
Why it matters
Feasibility is the foundation that everything downstream rests on — sample size, recruitment timelines, regulatory sequencing, budget. When feasibility is built on aspirational estimates and unvalidated assumptions, every downstream decision inherits that fragility. In oncology, where competition is intense and patient pools are narrow, the cost of a misjudged feasibility compounds at every stage.
What we offer
- Country and site feasibility analysis grounded in real-world data
- Indication-specific patient pool sizing
- Competing trial landscape mapping
- Investigator and site identification through our hospital network
- Enrollment forecasting with realistic, scenario-based projections
- Site qualification advisory
How we work
Our medical and biostatistical specialists work as one team — modeling the eligible patient population from real-world data, mapping the competing trial environment, and validating assumptions directly with our hospital partners. The output is a defensible site strategy, built on evidence sponsors can stand behind.
Related services
- Biostatistics — feasibility informs sample size and stratification
- Protocol Development — eligibility criteria calibrated to feasibility outputs
- IND Strategy — country selection feeds regulatory sequencing